Immunotherapy in the treatment of advanced or recurrent endometrial cancer
The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical advances in hematology & oncology : H&O - 22(2024), 3 vom: 15. Apr., Seite 129-139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grau-Bejar, Juan Francisco [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 10.04.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM370776615 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370776615 | ||
| 003 | DE-627 | ||
| 005 | 20240410232931.0 | ||
| 007 | tu | ||
| 008 | 240409s2024 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370776615 | ||
| 035 | |a (NLM)38588272 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grau-Bejar, Juan Francisco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy in the treatment of advanced or recurrent endometrial cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Farinas-Madrid, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a García-Duran, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a García-Illescas, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzeo, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Oaknin, Ana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical advances in hematology & oncology : H&O |d 2003 |g 22(2024), 3 vom: 15. Apr., Seite 129-139 |w (DE-627)NLM157777022 |x 1543-0790 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:3 |g day:15 |g month:04 |g pages:129-139 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 3 |b 15 |c 04 |h 129-139 | ||